Tevogen Bio is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and ...

We are excited to welcome Dr. Vincent, whose extensive drug development experience and expertise in translating groundbreaking science into therapies will be instrumental in leading our scientific ...

Q4 2024 Earnings Call Transcript March 27, 2025 INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.4, ...

Chief Information Officer & Head of Tevogen.AI at Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company ...

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.

Bluebird bio receives non-binding bid for up to $110.5 million Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million ...

WARREN, N.J., March 25, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company ... to its leadership team as Global Head of Government Affairs and Patient Access.

Q4 2024 Earnings Call Transcript March 20, 2025 TELA Bio, Inc. beats earnings expectations. Reported EPS is $-0.23, ...